Organization
Wake Forest Comprehensive Cancer Center
5 abstracts
Abstract
Novel HLA-Ilo/HLA-IIhi phenotype and immune evasion in triple-negative breast cancer.Org: Labcorp Oncology, OmniSeq Inc. (Labcorp), Roswell Park Comprehensive Cancer Center, Duke University Medical Center, Duke Cancer Institute,
Abstract
Interaction between VEGF-A and immune checkpoint targets in triple-negative breast cancer and mechanisms of immune evasion and tumor progression.Org: Labcorp Oncology, Roswell Park Comprehensive Cancer Center, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,
Abstract
A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Illumina Inc., Fortrea Inc.,
Abstract
Evaluating tumor inflammation and PD-L1 expression in sequential biopsies of real-world primary and metastatic breast cancer.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Duke University Medical Center, Duke Cancer Institute, Wake Forest Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC,
Abstract
Real-world clinical and genomic analysis of patients with a personal or family history of cancer undergoing germline testing for BRCA1 and BRCA2.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Duke University Medical Center, Wake Forest Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC, Research Triangle Park, NC,